Xiaorong Dong

4.9k total citations
124 papers, 1.9k citations indexed

About

Xiaorong Dong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Xiaorong Dong has authored 124 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 39 papers in Molecular Biology. Recurrent topics in Xiaorong Dong's work include Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Research Studies (28 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Xiaorong Dong is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Research Studies (28 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Xiaorong Dong collaborates with scholars based in China, United States and South Korea. Xiaorong Dong's co-authors include Gang Wu, Ruiguang Zhang, Fan Tong, Rui Meng, Shuangbing Xu, Yu Hu, Rui Zhou, Martin Kühne, Claudia E. Rübe and Christian Rübe and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Xiaorong Dong

110 papers receiving 1.9k citations

Peers

Xiaorong Dong
Wenjun Zhou China
Feng Zhao China
Mengnan Zhao China
Kimberly J. Krager United States
Haijuan Wang China
Marie Brevet France
Yue Gong China
Yoko Omoto Japan
Wenjun Zhou China
Xiaorong Dong
Citations per year, relative to Xiaorong Dong Xiaorong Dong (= 1×) peers Wenjun Zhou

Countries citing papers authored by Xiaorong Dong

Since Specialization
Citations

This map shows the geographic impact of Xiaorong Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaorong Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaorong Dong more than expected).

Fields of papers citing papers by Xiaorong Dong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaorong Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaorong Dong. The network helps show where Xiaorong Dong may publish in the future.

Co-authorship network of co-authors of Xiaorong Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaorong Dong. A scholar is included among the top collaborators of Xiaorong Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaorong Dong. Xiaorong Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Ye, et al.. (2025). Cyclin Y interacts with Chk1 to activate RRM2/STAT3 signaling and promotes radioresistance in non-small cell lung cancer. International Journal of Biological Sciences. 21(5). 1999–2011. 1 indexed citations
2.
Le, Xiuning, Xiaorong Dong, Herbert H. Loong, et al.. (2025). LBA75 Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study. Annals of Oncology. 36. S1617–S1617.
3.
4.
5.
Li, Zixuan, Jinsong Li, Zhikun Zheng, et al.. (2024). CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer. Journal of Experimental & Clinical Cancer Research. 43(1). 89–89. 11 indexed citations
6.
Chu, Tianqing, Xiaorong Dong, Huijuan Wang, et al.. (2024). Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors. European Journal of Cancer. 209. 114260–114260. 2 indexed citations
7.
Wang, Jie, Zhehai Wang, Yao Yu, et al.. (2024). Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8604–8604. 5 indexed citations
8.
Zhao, Jun, Jian Fang, Yan Yu, et al.. (2024). Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3008–3008. 12 indexed citations
9.
Zheng, Xuefeng, Zhi‐Wei Liu, Jiaojiao Wang, et al.. (2023). Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB/CTCF/p16 pathway. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(4). 166994–166994. 10 indexed citations
10.
Zhou, Qing, Lin Wu, Bo Jiang, et al.. (2023). Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.. Journal of Clinical Oncology. 41(16_suppl). 2570–2570. 4 indexed citations
11.
12.
13.
Rao, Xinrui, Zilong Wu, Yingzhuo Xu, et al.. (2023). Targeting polymerase θ impairs tumorigenesis and enhances radiosensitivity in lung adenocarcinoma. Cancer Science. 114(5). 1943–1957. 11 indexed citations
14.
Zhang, Yong, Li J, Xiaorong Dong, et al.. (2020). PSAT1 Regulated Oxidation-Reduction Balance Affects the Growth and Prognosis of Epithelial Ovarian Cancer. SHILAP Revista de lepidopterología. 1 indexed citations
15.
Xia, Yun, Wei Ye, Zhenyu Li, et al.. (2019). Catecholamines contribute to the neovascularization of lung cancer via tumor-associated macrophages. Brain Behavior and Immunity. 81. 111–121. 72 indexed citations
16.
Fang, Wenfeng, Shen Zhao, Ying Liang, et al.. (2018). P088 Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer. Journal of Thoracic Oncology. 13(12). S1080–S1080. 1 indexed citations
17.
Nie, Xinyi, et al.. (2016). Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations. SHILAP Revista de lepidopterología. 3 indexed citations
18.
Guo, Jing, Rui Meng, Zhongyuan Yin, et al.. (2016). A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles. Molecular Medicine Reports. 13(6). 4643–4653. 19 indexed citations
19.
Wang, Zhongliang, Tingting Du, Xiaorong Dong, et al.. (2016). Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress. International Journal of Oncology. 48(6). 2558–2566. 41 indexed citations
20.
Dong, Xiaorong, Ji-Hua Dong, Ruiguang Zhang, et al.. (2009). Anti-Inflammatory Effects of Tanshinone II A on Radiation-Induced Microglia BV-2 Cells Inflammatory Response. Cancer Biotherapy and Radiopharmaceuticals. 24(6). 681–687. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenjun Zhou Breakdown of academic impact, for papers by Feng Zhao Breakdown of academic impact, for papers by Mengnan Zhao Breakdown of academic impact, for papers by Kimberly J. Krager Breakdown of academic impact, for papers by Haijuan Wang Breakdown of academic impact, for papers by Marie Brevet Breakdown of academic impact, for papers by Yue Gong Breakdown of academic impact, for papers by Yoko Omoto
Rankless by CCL
2026